A snapshot of <scp>COVID</scp>‐19 infection in patients with solid tumors

Fuentes-Antrás, Jesús; Manzano, Aránzazu; Marquina, Gloria; Paz, Marina Matute De; Aguado, Carlos; Granja, Mónica; Benítez, J.C. Martín; Ortega, J. Domínguez; Priego, Araceli; González, Carlos; Tejerina-Peces, J.; Flores, Paloma; de, Alfonso López; Toledano, Carmen; Olalla, Jennifer; Luna, Alicia de; Bartolomé, J.; Pérez‐Segura, Pedro

doi:10.1002/ijc.33420

Cited by 9 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of 20,980 retrieved reports, 42 met study inclusion criteria 28 , 29 , 32 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 (Supplementary‐Figure 1). Study authors responded to requests to clarify the numbers and outcomes of IT patients receiving ICI therapy for 13 included reports 28 , 29 , 42 , 43 , 45 , 48 , 49 , 50 , 57 , 61 ,…”

Section: Resultsmentioning

confidence: 99%

“…Overall, results were indirect since only 4 studies (10%) specifically examined the impact of ICI therapy on outcomes, 46 , 52 , 55 , 56 and 13 studies required clarification from authors regarding the number and outcomes of patients receiving ICIs among all IT patients. 28 , 29 , 42 , 43 , 45 , 48 , 49 , 50 , 57 , 61 , 62 , 66 , 67 Finally, these findings are imprecise since only 1 study included >100 ICI patients while 37 had <50 and 26 had <10 ICI patients. Based on funnel plots and Egger's regression analysis ( p = 0.66, 0.31 and 0.19 for mortality, severe events and hospitalisation respectively) the outcome results did not appear subject to publication bias (Supplementary‐Figure 2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

Minkove

Sun

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

Background Determining how prior immune checkpoint inhibitor (ICI) therapy influences outcomes in cancer patients presenting with COVID‐19 is essential for patient management but must account for confounding variables. Methods We performed a systematic review and meta‐analysis of studies reporting adjusted effects of ICIs on survival, severe events, or hospitalisation in cancer patients with COVID‐19 based on variables including age, gender, diabetes mellitus, hypertension (HTN), chronic obstructive pulmonary disease, and other comorbidities. When adjusted effects were unavailable, unadjusted data were analysed. Results Of 42 observational studies (38 retrospective), 7 reported adjusted outcomes for ICIs and 2 provided sufficient individual patient data to calculate adjusted outcomes. In eight studies, adjusted outcomes were based on ≤7 variables. Over all studies, only one included >100 ICI patients while 26 included <10. ICIs did not alter the odds ratio (95%CI) (OR) of death significantly (random effects model), across adjusted ( n = 8) [1.31 (0.58–2.95) p = 0.46; I 2 = 42%, p = 0.10], unadjusted ( n = 30) [1.06 (0.85–1.32) p = 0.58; I 2 = 0%, p = 0.76] or combined [1.09 (0.88;1.36) p = 0.41; I 2 = 0%, p = 0.5)] studies. Similarly, ICIs did not alter severe events significantly across adjusted ( n = 5) [1.20 (0.30–4.74) p = 0.73; I 2 = 52%, p = 0.08], unadjusted ( n = 19) [(1.23 (0.87–1.75) p = 0.23; I 2 = 16%, p = 0.26] or combined [1.26 (0.90–1.77) p = 0.16; I 2 = 25%, p = 0.14] studies. Two studies provided adjusted hospitalisation data and when combined with 13 unadjusted studies, ICIs did not alter hospitalisation significantly [1.19 (0.85–1.68) p = 029; I 2 = 5%, p = 0.40]. Results of sensitivity analyses examining ICI effects based on 5 variables were inconclusive. Certainty of evidence was very low. Conclusions Across studies with adjusted and unadjusted results, ICIs did not alter outcomes significantly. But studies with comprehensive adjusted outcome data controlling for confounding variables are necessary to determine whether ICIs impact COVID‐19 outcomes in cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

Minkove

Sun

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Finally, the actual threat that the COVID-19 pandemic represents for oncological patients also needs to be considered ( 18 , 19 ). Given the discrete but reproducible antiviral effect of VS and especially OOS, and the fact that those products have demonstrated to be safe and well-tolerated in several clinical contexts ( 3-7 , 37 ), they may be considered in the fight against SARS-CoV-2 infections.…”

Section: Discussionmentioning

confidence: 99%

“…Current antitumoral agents, mostly those with chemotherapeutic properties, are known to affect the immune system, impairing it and, therefore, favoring infections ( 16 , 17 ). The actual scenario of the COVID-19 pandemic worsens such situations as immunocompromised patients appear particularly susceptible to the physiopathological consequences of SARS-CoV-2 infection ( 18 , 19 ). Therefore, supplements that may fight the infectivity of viruses should report benefits to patients under chemotherapeutic regimens or on those tumor types directly associated to viral infections, such as papillomavirus or hepatitis virus-promoted tumors ( 20 , 21 ).…”

Section: Introductionmentioning

confidence: 99%

Ocoxin oral solution demonstrates antiviral properties in cellular models

2021

View full text Add to dashboard Cite

Ocoxin Oral Solution (OOS) and Viusid (VS) are nutritional supplements that include several natural products which affect different cellular functions, such as proliferation or the redox status. In addition, some of their constituent components have been described to exert an antiviral effect. Considering this, it was hypothesized that treatment with OOS and VS could protect from viral infections. In order to evaluate the impact of OOS and VS on viral infection, lentivirus and retrovirus whose genomes coded for green fluorescent protein were used. In addition, and as a second approach to measure viral infection, a hemagglutinin-tagged form of the mitogen-activated protein kinase ERK5 was also inserted in the retroviral vector. Viral particles produced in 293T cells were used to infect HeLa cells in the presence or absence of OOS or VS. It was observed that VS had a minimal effect on the capacity of either lentivirus or retrovirus to infect HeLa cells. However, OOS significantly reduced the infection of HeLa cells with both of these viruses. The effect was dose-dependent, reaching a maximum at a 1:100 dilution of OOS. These results suggested that, in addition to its well-known antitumoral properties, OOS may also inhibit infection with viruses. This effect is relevant since patients receiving oncological therapies are more susceptible to viral infections, and nutritional supplements such as OOS may help in reducing the severity of these potential pathogenic infections.

show abstract

“…Cancer suppresses patients' immune systems, especially when they are older and have frequent diseases. Early reports on COVID-19 suggest that cancer patients are prone to be affected by COVID-19, and such patients usually present poor results [2][3][4][5][6][7][8]. As COVID-19 spreads rapidly and has a higher prevalence in cancer patients around the globe, it is imperative to define the risk factors, outcomes, and features of this group.…”

Section: Introductionmentioning

confidence: 99%

Clinical Presentations and Outcomes of Coronavirus Disease 2019 in Patients With Solid Tumors

Farooque¹,

Farooque²,

Karimi³

et al. 2021

Cureus

View full text Add to dashboard Cite

BackgroundCoronavirus disease 2019 (COVID-19) is a global health crisis. The literature suggests that cancer patients are more prone to be affected by COVID-19 because cancer suppresses the immune system and such patients usually present poor results. The objective of this study is to present all clinical, laboratory, and demographic characteristics of COVID-19 patients with solid tumors. MethodologyThis study was conducted at the Dow University of Health Sciences for a period of six months from April 2020 to September 2020. In this study, we included a total of 1,519 confirmed patients diagnosed with solid tumors via polymerase chain reaction. The mortality timeline within 30 days of contracting the virus was considered, and the median age of the included individuals was 61 years, with a range of 20-95 years. Of the patients included in the study, 49.4% (750) were men; moreover, 3.15% of our study population had prostate cancer, 10.20% had colorectal cancer, 2.76% had breast cancer, and 10.46% had lung cancer. Of the patients, 25.93% presented with at least one comorbidity. For 73% of the patients, at least one direct therapy for COVID-19 was included in the treatment; 56.6% of the patients were hospitalized, and 11.32% were admitted to the intensive care unit. ResultsThe mortality rate was 4.74% in the first 30 days after diagnosis, where 72 patients died. The findings of the first multi-variation model showed that males at older ages who were diabetic and going through cytotoxic therapy were prone to die within the first 30 days. However, the 30-day mortality rate was lower in patients diagnosed with prostate and breast cancer. The second set incorporated laboratory factors, where we found that higher values of leukocytosis, thrombocytopenia, and lymphocytopenia were correlated with higher rates of mortality within 30 days. ConclusionsWe conclude that there is a higher mortality rate of COVID-19 in patients with solid tumors than in the general population. However, it was found to be lower in the Pakistani population compared with the Chinese and Western populations. Intensive care can decrease mortality rates in COVID-19 and cancer patients.

show abstract

A snapshot of COVID‐19 infection in patients with solid tumors

Cited by 9 publications

References 22 publications

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

Ocoxin oral solution demonstrates antiviral properties in cellular models

Clinical Presentations and Outcomes of Coronavirus Disease 2019 in Patients With Solid Tumors

Contact Info

Product

Resources

About